MMP-1, UCH-L1, and 20S Proteasome as Potential Biomarkers Supporting the Diagnosis of Brain Glioma

Biomolecules. 2022 Oct 13;12(10):1477. doi: 10.3390/biom12101477.

Abstract

The diagnosis of brain gliomas is mainly based on imaging methods. The gold standard in this area is MRI. Recommendations for the prevention, diagnosis, and treatment of gliomas are periodically modified and updated. One of the diagnostic techniques used when a brain glioma is suspected is liquid biopsy. However, this technique requires further development to confirm its effectiveness. This paper presents a proposal of three potential biomarkers of brain gliomas-extracellular matrix metalloproteinase-1 (MMP-1), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and the 20S proteasome-which were quantified in blood plasma using SPRi biosensors. A statistical analysis of the results indicated no significant changes in the concentrations between the control group (K) and grades G1 and G2, and similarly between grades G3 and G4. However, the differences in the concentrations between the groups K/G1/G2 and G3/G4 were statistically significant. A positive average correlation was found between the concentrations of the proteins and the patient's age. The individual tested proteins were also highly correlated with each other. Our work proposes a new diagnostic technique that may aid in the diagnosis of brain gliomas.

Keywords: SPRi biosensor; biomedical research; glioma; liquid biopsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Brain / metabolism
  • Glioma* / diagnosis
  • Glioma* / pathology
  • Humans
  • Matrix Metalloproteinase 1 / metabolism
  • Proteasome Endopeptidase Complex / metabolism
  • Ubiquitin Thiolesterase* / metabolism

Substances

  • Ubiquitin Thiolesterase
  • Proteasome Endopeptidase Complex
  • Matrix Metalloproteinase 1
  • Biomarkers

Grants and funding

This research was funded by the Polish Ministry of Education and Science, grant number BST-162.